Signal
Lilly’s Next-Gen ADC Achieves 79 Percent Response Rate in Platinum-Sensitive Ovarian Cancer
- Category
- · Conference · Global
- Date
- October 24, 2026
- Source
- OVUM
Summary
Eli Lilly's sofetabart mipitecan (Sofe-M) combined with bevacizumab showed a 100% disease control rate in Phase 1 trials. The folate receptor alpha-targeting ADC maintains efficacy across all expression levels and in patients previously treated with PARP inhibitors, signaling a potential new standard of care.
Who gathers around Oncology is an early sign of where the field is putting its attention. The speaker list and the sponsors usually tell you more than the agenda does.
OVUM interpretation layer
The editorial read on this signal — pattern, market-structure implications, and what to watch next.
Sources
- OVUM Primary source
The OVUM Intelligence Brief
Keep reading past this page
The week's funding, launches, and studies in women's health, in plain English.
Weekly. No spam. Unsubscribe anytime.